Crosslay Laboratories Private Limited
About Crosslay Laboratories Private Limited
Data last updated:
Crosslay Laboratories Private Limited is a private limited company based in Delhi, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 28 July 1998 and has been in existence for over 28 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL1998PTC095215.
The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹15 Lakh. It is led by directors Nitin Kumar Bansal and Anjali Bansal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1146 Prem Gali Kashmiri Gate, Delhi, India – 110006.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.11 Lakh, a growth of 11% compared to the previous year. For the same year it recorded a net profit of ₹2.81 Lakh (net margin 68.4%) and EBITDA of ₹3.76 Lakh (EBITDA margin 91.4%). Revenue has declined at a compounded annual rate (CAGR) of 16% over three years and 45% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Crosslay Laboratories Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address1146 Prem Gali Kashmiri Gate, Delhi, India – 110006
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Crosslay Laboratories Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Crosslay Laboratories Private Limited
FY 2025 filings availableCrosslay Laboratories Private Limited reported revenue of ₹4.11 Lakh (up 11% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 11% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 45%. EBITDA rose 13% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.76 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.81 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 91.4% | ||||
| Net Profit Margin | 68.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Crosslay Laboratories Private Limited, buy the company report.
Board of directors of Crosslay Laboratories Private Limited
Crosslay Laboratories has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nitin Kumar Bansal | Director | 28 Jul 1998 | 28 Years 3 Months | Current |
| Anjali Bansal | Director | 30 Jul 2025 | 1 Years 3 Months | Current |
Auditor
Crosslay Laboratories Private Limited is audited by VIPIN OM & Associates for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VIPIN OM & Associates | FY 2017 | 509191C |
Shareholding
The shareholding of Crosslay Laboratories Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Crosslay Laboratories Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Crosslay Laboratories Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Crosslay Laboratories Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Crosslay Laboratories Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Crosslay Laboratories Private Limited has 5 board changes on record since 1998: 3 appointments and 2 cessations. The latest: Anjali Bansal ceased to be Additional Director on 29 Sep 2025.
Frequently asked questions
Crosslay Laboratories is an active private limited company based in Delhi, India. The company works in chemical products, within the chemicals industry. It was incorporated on 28 July 1998 (28+ years old) and is registered under CIN U24232DL1998PTC095215.
Crosslay Laboratories has 2 current directors:
- Nitin Kumar Bansal - Director
- Anjali Bansal - Director
The latest financial statements of Crosslay Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Crosslay Laboratories is U24232DL1998PTC095215. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Crosslay Laboratories was incorporated on 28 July 1998, making it 28+ years old. It is registered with the Registrar of Companies, Delhi.
Anjali Bansal ceased to be Additional Director on 29 Sep 2025. Anjali Bansal was appointed as Director on 30 Jul 2025. Nawal Kishore Bansal ceased to be Director on 13 Jul 2025. Crosslay Laboratories has 5 board changes on record in total.
The registered office of Crosslay Laboratories is at 1146 Prem Gali Kashmiri Gate, Delhi, India – 110006.
Crosslay Laboratories operates in the chemicals industry, in the chemical products segment.
The compliance status of Crosslay Laboratories is compliant as of 08 August 2026. The company is actively filing with the Registrar of Companies.
Crosslay Laboratories can be reached at its registered office: 1146 Prem Gali Kashmiri Gate, Delhi, India – 110006.